Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
Go back to Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 528.90 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $528.90 | 52 Week High | $134.71 | |||
| Open | $528.90 | 52 Week Low | $73.31 | |||
| Day High | $528.90 | P/E | N/A | |||
| Day Low | $528.90 | EPS | $-1.98 | |||
| Volume | 436 | |||||
